ClinicalTrials.gg
CompletedNCT04278924Updated Jun 15, 2025Results posted

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

A Phase 2 interventional study of Placebo and TAK-079 in Primary Immune Thrombocytopenia, sponsored by Takeda. Completed at 55 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain — 14 open to participants now, 18 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Spain.

Enrollment
33rd of 44
41 · median 69
Started
2020
with 4 others
Phase 2
11 of 50
1 open now
Registered
22nd of 50
by date
Lead sponsor
3 of 50
Takeda

Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, this one is the 33rd largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2020, is one of 11 in phase 2, and was the 22nd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

14 of the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, or all of them as a file.
02

Study summary

Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of platelets - the cells that help blood clot.

The main aim of the study is to check for side effects from taking TAK-079 at three different dose levels. Another aim is to learn if TAK-079 can increase the platelet count in people with ITP.

In addition to receiving stable background therapy for ITP, participants will receive an injection of either TAK-079 or a placebo once a week for 2 months. A placebo looks like TAK-079 but will not have any medicine in it. After treatment, all participants will be followed-up for another 2 months.

Then, participants who received TAK-079 will continue to be followed-up for an extra 4 months. Participants who received the placebo and would like to receive TAK-079 may be able to do this in an extension period in the study.

Read the detailed description

The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat people who have primary immune thrombocytopenia (ITP). This study will evaluate the safety and biologic activity of TAK-079 or matching placebo in combination with stable ITP background therapy.

The study will enroll approximately 36 to 54 participants. In Part A of the study, participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups. Those who received placebo in this period will have the choice to receive TAK-079 after a safety follow-up period and will be randomized to one of the two open-label TAK-079 treatment arms. An unblinded safety review will take place once a minimum of 24 evaluable participants are available for analysis in Part A to decide whether to open enrollment into Part B.

In Part B participants will be randomly assigned to one of two treatment groups. Those who received placebo in this period will have the choice to receive study drug after a safety follow-up period in a single open-label TAK-079 treatment arm.

This multi-center trial will be conducted worldwide. All participants will be followed for at least 8 weeks in a Safety Follow-up Period, and a 16-week Long-term Follow-up Period after the 8 weeks of treatment.

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with ITP that has persisted for ≥3 months, diagnosed in accordance to The American Society of Hematology 2011 Evidence-based Practice Guideline for Immune Thrombocytopenia or the International Consensus Report on The Investigation and Management of Primary Immune Thrombocytopenia as locally applicable.
  2. Has a mean count of \<30,000/μL (and individually ≤35,000/μL) on at least 2 measurements at least 1 week apart during screening.
  3. Diagnosis of ITP supported by a prior response to an ITP therapy (other than a thrombopoietin receptor agonists [TPO-RA]) that achieved a platelet count of ≥50,000/μL.
  4. If receiving standard background treatment for ITP, treatment should be stable in dose and frequency for at least 4 weeks before dosing.

    1. Permitted standard background treatments may include: 1 oral ; ±1 from the following list: azathioprine, danazol, dapsone, cyclosporine, mycophenolate mofetil, mycophenolate sodium; ±1 TPO-RA (romiplostim, eltrombopag, avatrombopag); ±fostamatinib. Corticosteroids, including dexamethasone, must be given as oral, daily or every-other-day therapy as opposed to pulse therapy.
    2. The dose of any permitted standard background therapy must be expected to remain stable through the study, unless dose reduction is required because of toxicities.

Exclusion criteria

Exclusion Criteria:

  1. Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within 3 weeks before screening.
  2. Has a history of any thrombotic or embolic event within 12 months before screening.
  3. Has a history of splenectomy within 3 months before screening.
  4. Use of intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin or anti-D immunoglobulin treatment within 4 weeks of screening, or an expectation that any therapy besides the participant's standard background therapies may be used for treatment of thrombocytopenia (e.g., a rescue therapy) between screening and dosing.
  5. Diagnosed with (COPD) or asthma, and a prebronchodilatory (FEV1) \<50% of predicted normal.
  6. Use of rituximab or any monoclonal antibody (mAb) for immunomodulation within 4 months before first dosing. Note: Participants with prior exposure to rituximab must have cluster of differentiation (CD) 19 counts within the normal range at screening.
  7. Use of (such as cyclophosphamide, vincristine) other than permitted oral immunosuppressants within 6 months before first dosing.
  8. Has been diagnosed with myelodysplastic syndrome.
  9. Has received a within 4 weeks before screening or has any live vaccine planned during the study.

10 Has had an opportunistic infection ≤12 weeks before initial study dosing or is currently undergoing treatment for a chronic opportunistic infection, such as tuberculosis (TB), pneumocystis pneumonia, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Placebo comparator
    Part A & B: Double Blind Period: Placebo

    Participants received TAK-079 placebo-matching injection subcutaneously (SC), once weekly (QW) for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded short follow-up period (SFP) up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in Open-label Extension (OLE) Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded long follow-up period (LFP) up to Week 32.

    Drug: Placebo

  • Experimental
    Part A: Double Blind Period: TAK-079 100 mg

    Participants received TAK-079 100 mg, SC injection, QW for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded SFP up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in OLE Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded LFP up to Week 32.

    Drug: TAK-079

  • Experimental
    Part A: Double Blind Period: TAK-079 300 mg

    Participants received TAK-079 300 mg, SC injection, QW for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded SFP up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in OLE Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded LFP up to Week 32.

    Drug: TAK-079

  • Experimental
    Part B: Double Blind Period: TAK-079 600 mg

    Participants received TAK-079 600 mg, SC injection, QW for 8 weeks. Following treatment participants were followed up for 8 weeks in a double blinded SFP up to Week 16. Participants who opted to receive treatment with TAK-079 were then randomized to receive TAK-079, SC injection, QW for 8 weeks in OLE Period of Part A or Part B. Participants who did not opt to receive treatment with TAK-079 were followed up for another 16 weeks in an unblinded LFP up to Week 32.

    Drug: TAK-079

  • Experimental
    Part A: Open-label Extension (OLE) Period: TAK-079 100 mg

    Participants who received placebo in double-blind Part A and opted to receive treatment with TAK-079 were randomized to receive TAK-079 100 mg, SC injection, QW for 8 weeks in OLE Period of Part A. Following treatment participants were followed up for 8 weeks in a SFP and then for another 16 weeks in a LFP.

    Drug: TAK-079

  • Experimental
    Part A: OLE Period: TAK-079 300 mg

    Participants who received placebo in double-blind Part A and opted to receive treatment with TAK-079 were randomized to receive TAK-079 300 mg, SC injection, QW for 8 weeks in OLE Period of Part A. Following treatment participants were followed up for 8 weeks in a SFP and then for another 16 weeks in a LFP.

    Drug: TAK-079

  • Experimental
    Part B: OLE Period: TAK-079 600 mg

    Participants who received placebo in double-blind Part B and opted to receive treatment with TAK-079 received TAK-079 600 mg, SC injection, QW for 8 weeks in OLE Period of Part B. Following treatment participants were followed up for 8 weeks in a SFP and then for another 16 weeks in a LFP.

    Drug: TAK-079

Interventions

  • DrugPlacebo

    TAK-079 placebo-matching SC injection.

  • TAK-079 SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading to TAK-079 Discontinuation

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with the treatment. SAE means any untoward medical occurrence that at any dose: a) results in death; b) is life-threatening; c) requires inpatient hospitalization or prolongation of an existing hospitalization; d) results in persistent or significant disability or incapacity; e) is a congenital anomaly/birth defect; f) is a medically important event. TEAEs were defined as an AE having a start date and time equal to or later than the start date and time of the first dose of investigational medicinal product (IMP). Percentages were rounded off to the nearest single decimal place.

    Time frame: Up to Week 32 in each Period of the study

Secondary outcomes

  1. Percentage of Participants With Platelet Response at Weeks 16 and 32

    Platelet response is defined as a platelet count ≥50,000/microliter (μL) and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

    Time frame: At Weeks 16 and 32

  2. Percentage of Participants With Complete Platelet Response at Weeks 16 and 32

    Complete platelet response is defined as a platelet count ≥100,000/μL on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

    Time frame: At Weeks 16 and 32

  3. Percentage of Participants With Clinically Meaningful Platelet Response at Weeks 16 and 32

    A clinically meaningful platelet response is defined as a platelet count ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

    Time frame: At Weeks 16 and 32

  4. Percentage of Participants With Hemostatic Platelet Response at Weeks 16 and 32

    A hemostatic platelet response is defined for participants with a baseline platelet count of \<15,000/μL who achieved a platelet count of ≥30,000/μL and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

    Time frame: At Weeks 16 and 32

07

Results

Posted Jun 15, 2025

Participant flow

Participants took part in the study at 24 investigative sites globally from 09 November 2020 to 29 April 2024.

Double Blind Period (Main Study)
Participant flow — Double Blind Period (Main Study)
MilestonePart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Started139811000
Completed12789000
Not completed1202000
Withdrew: Withdrawal by subject1102000
Withdrew: Reason not specified0100000
Open-label Extension Period
Participant flow — Open-label Extension Period
MilestonePart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Started0000444
Completed0000444
Not completed0000000

Outcome measures

PrimaryPercentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading to TAK-079 Discontinuation

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with the treatment. SAE means any untoward medical occurrence that at any dose: a) results in death; b) is life-threatening; c) requires inpatient hospitalization or prolongation of an existing hospitalization; d) results in persistent or significant disability or incapacity; e) is a congenital anomaly/birth defect; f) is a medically important event. TEAEs were defined as an AE having a start date and time equal to or later than the start date and time of the first dose of investigational medicinal product (IMP). Percentages were rounded off to the nearest single decimal place.

Time frame:
Up to Week 32 in each Period of the study
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading to TAK-079 Discontinuation
percentage of participantsPart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Grade 3 or Higher TEAE23.122.2027.30025.0
Treatment Emergent SAE7.722.2018.225.000
TEAEs Leading to TAK-079 Discontinuation022.2018.225.000
SecondaryPercentage of Participants With Platelet Response at Weeks 16 and 32

Platelet response is defined as a platelet count ≥50,000/microliter (μL) and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

Time frame:
At Weeks 16 and 32
Reported as:
Number · percentage of participants
Percentage of Participants With Platelet Response at Weeks 16 and 32
percentage of participantsPart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Week 1623.08 (5.04 to 53.81)66.67 (29.93 to 92.51)62.50 (24.49 to 91.48)90.91 (58.72 to 99.77)50.00 (6.76 to 93.24)50.00 (6.76 to 93.24)25.00 (0.63 to 80.59)
Week 32—66.67 (29.93 to 92.51)62.50 (24.49 to 91.48)90.91 (58.72 to 99.77)50.00 (6.76 to 93.24)50.00 (6.76 to 93.24)25.00 (0.63 to 80.59)
Statistical analysis
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 100 mg · Barnard's test · p = =0.056 · Risk difference (rd): 43.59 · 95% CI 0.81 to 73.3595% confidence interval (CI) of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 300 mg · Barnard's test · p = =0.088 · Risk difference (rd): 39.42 · 95% CI -4.24 to 71.3895% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part B: Double Blind Period: TAK-079 600 mg · Barnard's test · p = =0.001 · Risk difference (rd): 67.83 · 95% CI 29.21 to 87.2995% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
SecondaryPercentage of Participants With Complete Platelet Response at Weeks 16 and 32

Complete platelet response is defined as a platelet count ≥100,000/μL on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

Time frame:
At Weeks 16 and 32
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Platelet Response at Weeks 16 and 32
percentage of participantsPart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Week 160 (0.00 to 24.71)55.56 (21.20 to 86.30)50.00 (15.70 to 84.30)81.82 (48.22 to 97.72)0 (0.00 to 60.24)25.00 (0.63 to 80.59)25.00 (0.63 to 80.59)
Week 32—55.56 (21.20 to 86.30)50.00 (15.70 to 84.30)81.82 (48.22 to 97.72)25.00 (0.63 to 80.59)25.00 (0.63 to 80.59)25.00 (0.63 to 80.59)
Statistical analysis
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 100 mg · Barnard's test · p = =0.001 · Risk difference (rd): 55.56 · 95% CI 25.11 to 81.5195% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 300 mg · Barnard's test · p = =0.004 · Risk difference (rd): 50 · 95% CI 19.63 to 78.9595% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part B: Double Blind Period: TAK-079 600 mg · Barnard's test · p = <0.001 · Risk difference (rd): 81.82 · 95% CI 51.24 to 94.9995% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
SecondaryPercentage of Participants With Clinically Meaningful Platelet Response at Weeks 16 and 32

A clinically meaningful platelet response is defined as a platelet count ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

Time frame:
At Weeks 16 and 32
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Meaningful Platelet Response at Weeks 16 and 32
percentage of participantsPart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Week 1630.77 (9.09 to 61.43)66.67 (29.93 to 92.51)75.00 (34.91 to 96.81)90.91 (58.72 to 99.77)75.00 (19.41 to 99.37)50.00 (6.76 to 93.24)25.00 (0.63 to 80.59)
Week 32—66.67 (29.93 to 92.51)75.00 (34.91 to 96.81)90.91 (58.72 to 99.77)75.00 (19.41 to 99.37)50.00 (6.76 to 93.24)25.00 (0.63 to 80.59)
Statistical analysis
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 100 mg · Barnard's test · p = =0.120 · Risk difference (rd): 35.9 · 95% CI -7.22 to 67.7595% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 300 mg · Barnard's test · p = =0.060 · Risk difference (rd): 44.23 · 95% CI -0.83 to 73.7795% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part B: Double Blind Period: TAK-079 600 mg · Barnard's test · p = =0.003 · Risk difference (rd): 60.14 · 95% CI 21.33 to 82.4295% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
SecondaryPercentage of Participants With Hemostatic Platelet Response at Weeks 16 and 32

A hemostatic platelet response is defined for participants with a baseline platelet count of \<15,000/μL who achieved a platelet count of ≥30,000/μL and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy. Percentages were rounded off to the nearest single decimal place.

Time frame:
At Weeks 16 and 32
Reported as:
Number · percentage of participants
Percentage of Participants With Hemostatic Platelet Response at Weeks 16 and 32
percentage of participantsPart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Week 160 (0.00 to 52.18)40.00 (5.27 to 85.34)25.00 (0.63 to 80.59)100.00 (39.76 to 100.00)100.00 (15.81 to 100.00)100.00 (2.50 to 100.00)0 (0.00 to 70.76)
Week 32—40.00 (5.27 to 85.34)25.00 (0.63 to 80.59)100.00 (39.76 to 100.00)100.00 (15.81 to 100.00)100.00 (2.50 to 100.00)0 (0.00 to 70.76)
Statistical analysis
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 100 mg · Barnard's test · p = =0.187 · Risk difference (rd): 40 · 95% CI -16.28 to 78.1795% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part A: Double Blind Period: TAK-079 300 mg · Barnard's test · p = =0.315 · Risk difference (rd): 25 · 95% CI -28.85 to 71.7895% CI of the difference in percentage was calculated using Miettinen-Nurminen method.
  • Part A & B: Double Blind Period: Placebo vs Part B: Double Blind Period: TAK-079 600 mg · Barnard's test · p = =0.004 · Risk difference (rd): 100 · 95% CI 35.12 to 100.0095% CI of the difference in percentage was calculated using Miettinen-Nurminen method.

Adverse events

Collected over Up to Week 32 in each Period of the study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A & B: Double Blind Period: Placebo0/13 (0%)1/13 (7.7%)9/13 (69.2%)
Part A: Double Blind Period: TAK-079 100 mg0/9 (0%)2/9 (22.2%)7/9 (77.8%)
Part A: Double Blind Period: TAK-079 300 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
Part B: Double Blind Period: TAK-079 600 mg0/11 (0%)2/11 (18.2%)6/11 (54.5%)
Part A: Open-label Extension (OLE) Period: TAK-079 100 mg0/4 (0%)1/4 (25%)2/4 (50%)
Part A: OLE Period: TAK-079 300 mg0/4 (0%)0/4 (0%)4/4 (100%)
Part B: OLE Period: TAK-079 600 mg0/4 (0%)0/4 (0%)2/4 (50%)
Most frequent serious events
Most frequent serious events
EventPart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
COVID-19Infections and infestations0/130/90/80/111/40/40/4
Conjunctivitis allergicEye disorders0/131/90/80/110/40/40/4
Immune thrombocytopeniaBlood and lymphatic system disorders0/131/90/80/110/40/40/4
Staphylococcal bacteraemiaInfections and infestations0/131/90/80/110/40/40/4
Acute kidney injuryRenal and urinary disorders0/130/90/81/110/40/40/4
Pyelonephritis chronicInfections and infestations0/130/90/81/110/40/40/4
ThrombocytopeniaBlood and lymphatic system disorders0/130/90/81/110/40/40/4
Haemorrhagic ovarian cystReproductive system and breast disorders1/130/90/80/110/40/40/4
Most frequent other events
Showing 10 of 77
Most frequent other events
EventPart A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgPart A: Open-label Extension (OLE) Period: TAK-079 100 mgPart A: OLE Period: TAK-079 300 mgPart B: OLE Period: TAK-079 600 mg
Abdominal painGastrointestinal disorders0/130/92/80/110/40/40/4
AnaemiaBlood and lymphatic system disorders0/130/92/80/110/40/40/4
Anal fissureGastrointestinal disorders0/130/90/80/110/41/40/4
AstheniaGeneral disorders2/130/90/80/110/40/41/4
COVID-19Infections and infestations1/132/90/81/111/40/40/4
ChillsGeneral disorders0/130/90/80/110/41/40/4
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/130/90/80/110/40/41/4
Conjunctival haemorrhageEye disorders2/131/90/80/111/40/40/4
ContusionInjury, poisoning and procedural complications2/130/90/80/110/40/41/4
DizzinessNervous system disorders0/130/90/80/110/41/40/4

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgTotal
Mean38.8 ± 15.8649.0 ± 14.4552.3 ± 16.5948.4 ± 19.6846.2 ± 17.03
Sex: Female, Male
Sex: Female, Male(Participants)Part A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgTotal
Female955928
Male443213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgTotal
Hispanic or Latino10001
Not Hispanic or Latino1298938
Unknown or Not Reported00022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A & B: Double Blind Period: PlaceboPart A: Double Blind Period: TAK-079 100 mgPart A: Double Blind Period: TAK-079 300 mgPart B: Double Blind Period: TAK-079 600 mgTotal
American Indian or Alaska Native00000
Asian10023
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1198937
More than one race00000
Unknown or Not Reported10001
08

Study locations

55 sites
  • Arizona Clinical Research Center - Hunt - PPDS
    Tucson, Arizona 85715, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Bleeding and Clotting Disorders Institute
    Peoria, Illinois 61614-3542, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Medical Center
    Boston, Massachusetts 02118-2905, United States
  • Leo W. Jenkins Cancer Center
    Greenville, North Carolina 27834, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda
    Sofia, Sofia-Grad 1407, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sofiamed OOD
    Sofia, Sofia-Grad 1750, Bulgaria
  • University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski EAD
    Pleven, 5800, Bulgaria
  • University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD
    Plovdiv, 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD
    Sofia, 1431, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
    Sofia, 1606, Bulgaria
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
  • Clinical Hospital Centre Osijek
    Osijek, 31000, Croatia
  • Klinicki bolnicki centar Zagreb
    Zagreb, 10000, Croatia
  • University Hospital Merkur
    Zagreb, 10000, Croatia
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Onkologische Schwerpunktpraxis Kurfurstendamm
    Berlin, 10707, Germany
  • OnkoNet Marburg GmbH
    Marburg, 35037, Germany
  • Rotkreuzklinikum Munchen
    Munchen, 80634, Germany
  • University General Hospital of Patras
    Patra, Achaia 26500, Greece
  • General Hospital of Athens - George Gennimatas
    Athens, Attiki 115 27, Greece
  • Georgios Papanikolaou General Hospital of Thessaloniki
    Thessaloniki, 57010, Greece
  • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)
    Trieste, Friuli-Venezia Giulia 34149, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milano, Lombardia 20122, Italy
  • Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi
    Catania, Sicilia 95122, Italy
  • Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80131, Italy
  • A.O.U. Maggiore della Carita
    Novara, 20100, Italy
  • Azienda Policlinico Umberto I
    Roma, 161, Italy
  • Nihon University Itabashi Hospital
    Itabashi, Tokyo 173-8610, Japan
  • Saiseikai Central Hospital
    Minato-Ku, Tokyo 108-0073, Japan
  • Univerzitetni klinicni Center Ljubljana
    Ljubljana, 1000, Slovenia
  • University Clinical Centre Maribor
    Maribor, 2000, Slovenia
  • Hospital Universitario Central de Asturias
    Oviedo, Asturias 33006, Spain
  • Corporacio Sanitaria Parc Tauli
    Sabadell, Barcelona 8208, Spain
  • Hospital Universitario Principe de Asturias
    Meco, Madrid 28880, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 8041, Spain
  • C.A.U de Burgos - Hospital Universitario de Burgos
    Burgos, 9005, Spain
  • Hospital Universitario Quironsalud Madrid
    Madrid, 28006, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28026, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Virgen del Rocio - PPDS
    Malaga, 29010, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Municipal Non-profit Enterprise Mykolayiv Regional Clinical Hospital the Mykolayiv Regional Council
    Mykolaiv, Mykolaivs'ka Oblast 54058, Ukraine
  • Municipal Non-profit Enterprise Ternopil Regional Clinical Hospital of Ternopil Regional Council
    Ternopil, Ternopil's'ka Oblast 46002, Ukraine
  • MNE Regional Clinical Hospital n a O F Herbachevskyi of Zhytomyr Regional Council
    Zhytomyr, Zhytomyrs'ka Oblast 10002, Ukraine
  • Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council - PPDS
    Dnipro, 49102, Ukraine
  • Medical Center OK!Clinic+LLC International Institute of Clinical Research
    Kyiv, 2091, Ukraine
  • CNE Kyiv City Clinical Hospital #9 of Exec. Body of Kyiv City Council Kyiv City State Admin
    Kyiv, 4060, Ukraine
  • State Institution Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine
    Lviv, 79044, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2024, 41 months.

Results were first posted in Jun 2025, 1 year 1 month after primary completion.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2020
First posted
Feb 20, 2020
StartActual
Nov 9, 2020
Primary completionActual
Apr 29, 2024
CompletionActual
Apr 29, 2024
Results first posted
Jun 15, 2025
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04278924
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 20, 2020
Start date
Nov 9, 2020
Primary completion
Apr 29, 2024
Completion
Apr 29, 2024
Results posted
Jun 15, 2025
Last update
Jun 15, 2025

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezagitamab

Start the discussion